Patents Examined by Gabriele E. Bugalsky
  • Patent number: 6538122
    Abstract: Disclosed are a protein having a transglutaminase activity, which comprises a sequence ranging from serine residue at the second position to proline residue at the 331st position in an amino acid sequence represented by SEQ ID No. 1 wherein the N-terminal amino acid of the protein corresponds to serine residue at the second position of SEQ ID No. 1, a DNA encoding the protein, a transformant having the DNA, and a process for producing a protein having a transglutaminase activity, which comprises the steps of culturing the transformant in a medium. The protein can be produced in a large amount with the transformant using a host such as E. coli.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: March 25, 2003
    Assignee: Ajinomoto Co., Inc.
    Inventors: Keiichi Yokoyama, Nami Nakamura, Tetsuya Miwa, Katsuya Seguro
  • Patent number: 6500626
    Abstract: A Bcl-2 associated protein (Bax) and uses thereof.
    Type: Grant
    Filed: August 24, 1999
    Date of Patent: December 31, 2002
    Assignee: Washington University
    Inventor: Stanley J. Korsmeyer
  • Patent number: 6242669
    Abstract: Disclosed and claimed are novel Bacillus thuringiensis isolates, pesticidal toxins, genes, and nucleotide probes and primers for the identification of genes encoding toxins active against pests. The primers are useful in PCR techniques to produce gene fragments which are characteristic of genes encoding these toxins. The subject invention provides entirely new families of toxins from Bacillus isolates.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: June 5, 2001
    Assignee: Mycogen Corporation
    Inventors: Jerald S. Feitelson, H. Ernest Schnepf, Kenneth E. Narva, Brian A. Stockhoff, James Schmeits, David Loewer, Charles Joseph Dullum, Judy Muller-Cohn, Lisa Stamp, George Morrill, Stacey Finstad-Lee
  • Patent number: 5962301
    Abstract: Described herein is the discovery that human interleukin-1.beta. convertase (ICE) is structurally similar to the protein encoded by the C. elegans cell death gene, ced-3. Comparative and mutational analyses of the two proteins, together with previous observations, suggest that the Ced-3 protein may be a cysteine protease like ICE and that ICE may be a human equivalent of the nematode cell death gene. Another mammalian protein, the murine NEDD-2 protein, was also found to be similar to Ced-3. The NEDD-2 gene is implicated in the development of the murine central nervous system. On the basis of these findings, novel drugs for enhancing or inhibiting the activity of ICE, ced-3, or related genes are provided. Such drugs may be useful for treating inflammatory diseases and/or diseases characterized by cell deaths, as well as cancers, autoimmune disorders, infections, and hair growth and hair loss. Furthermore, such drugs may be useful for controlling pests, parasites and genetically engineered organisms.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: October 5, 1999
    Assignee: Massachusetts Institute of Technology
    Inventors: H. Robert Horvitz, Junying Yuan, Shai Shaham
  • Patent number: 5919450
    Abstract: The invention provides a human glutathione S-transferase (GSTH) and polynucleotides which identify and encode GSTH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of GSTH.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: July 6, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
  • Patent number: 5834296
    Abstract: A novel crystal protein as an effective ingredient in harmful organism controlling agents, Bacillus thuringiensis var. japonensis strain N141 producing the protein, and a gene coding for the protein. This novel strain produces an insecticidal crystal toxin and is useful for a harmful organism controlling agent.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: November 10, 1998
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Toshihiko Iizuka, Michito Tagawa, Satoshi Arai, Masatsugu Niizeki, Toshiro Miyake
  • Patent number: 5834262
    Abstract: An improved process for preparing glyoxylic acid comprising using the enzyme glycolate oxidase in the form of permeabilized microbial cell transformants selected from Aspergillus nidulans, Hansenula polymorpha, Pichia pastoris and Escherichia coli to oxidize glycolic acid with oxygen in an aqueous solution that includes an amine.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: November 10, 1998
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: David Leroy Anton, Robert DiCosimo
  • Patent number: 5821224
    Abstract: The present invention provides a new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils herein named beta defensins. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. These antimicrobial compounds are useful in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: October 13, 1998
    Assignee: Regents of the University of California
    Inventors: Michael E. Selsted, James S. Cullor
  • Patent number: 5814481
    Abstract: The present invention provides a novel heat shock-like protein (HSPRO) and polynucleotides which identify and encode HSPRO. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of HSPRO.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: September 29, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah
  • Patent number: 5736131
    Abstract: The present invention provides, inter allia, a B.t. hybrid toxin fragment comprising at its C-terminal domain III of a first Cry protein or a part of the domain or a protein substantially similar to the domain, with the proviso that the N-terminal region of the fragment is the N-terminal region of a second Cry protein or a part of the region or a protein substantially similar to the region.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: April 7, 1998
    Assignee: Sandoz Ltd.
    Inventors: Hendrik Jan Bosch, Willem Johannes Stiekema
  • Patent number: 5690930
    Abstract: The cDNA which encodes heme-regulated eIF-2.alpha. kinase (HRI) has been cloned from a lambda Zap II cDNA library of rabbit reticulocytes. The rabbit HRI cDNA is highly homologous to human HRI and hybridizes to the human HRI DNA under moderately stringent conditions. The rabbit HRI cDNA contains 2729 amino acids. In vitro translation of HRI mRNA transcribed from HRI cDNA yields a 90 kDa polypeptide with eIF-2.alpha. kinase activity. Since HRI is a potent inhibitor of protein synthesis, it is anti-proliferative in nature. In addition, the unusually high degree of homology of HRI to three protein kinases involved in the regulation of cell division suggests that HRI plays a direct role in the regulation of cell division.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: November 25, 1997
    Assignee: Massachusetts Institute of Technology
    Inventors: Jane-Jane Chen, Irving M. London
  • Patent number: 5674846
    Abstract: This invention relates to an insecticidally effective peptide isolated from the spider, Segestria sp., characterized by its paralytic effect on insect pests and low mammalian toxicity. This invention also discloses methods for producing recombinant peptides, as well as methods of utilizing these peptides as insecticidal agents.
    Type: Grant
    Filed: September 4, 1996
    Date of Patent: October 7, 1997
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Janice H. Johnson, Robert M. Kral, Jr.
  • Patent number: 5643768
    Abstract: A method for the cell-free synthesis and isolation of novel genes and polypeptides is provided. Within one embodiment, an expression unit is constructed onto which semi-random nucleotide sequences are attached. The semi-random nucleotide sequences are first transcribed to produce RNA, and then translated under conditions such that polysomes are produced. Polysomes which bind to a substance of interest are then isolated and disrupted; and the released mRNA is recovered. The mRNA is used to construct cDNA which is expressed to produce novel polypeptides.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 1, 1997
    Assignee: Optein, Inc.
    Inventor: Glenn H. Kawasaki
  • Patent number: 5635182
    Abstract: Provided by the present invention are novel methods of detecting ligand interactions, as well as regents useful in the method, including DNA and host cells; and more specifically relates to novel methods for the detection of protein/protein interactions and their application in epitope mapping and the study of ligand/receptor interactions. Also provided are vaccines and kits comprising the expression products and host cells of the invention.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: June 3, 1997
    Assignee: Genetics Institute, Inc.
    Inventors: John M. McCoy, Zhijian Lu
  • Patent number: 5550049
    Abstract: DNAs encoding voltage-activated cation channels have been cloned and characterized. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the channel activity, and channel modulators are identified. Channel modulators are useful as insecticides and arachnicidic agents.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: August 27, 1996
    Assignee: Merck & Co., Inc
    Inventors: Leonardus H. T. Van Der Ploeg, Jeffrey W. Warmke
  • Patent number: 5505943
    Abstract: Compositions and methods of use are provided for debriding and wound healing applications.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 9, 1996
    Assignee: W. R. Grace & Co.-Conn.
    Inventors: Donald Z. Fortney, Donald R. Durham
  • Patent number: 5308762
    Abstract: A T4 endonuclease V DNA repair enzyme contains an amino acid sequence within its carboxyl terminal region which is involved in dimer specific binding. The region includes polar nonaromatic basic amino acids and aromatic amino acids between amino acid 128 to 137 positions. The specific activity of the enzyme is greatly increased at low salt concentrations when substitutions are made in aromatic amino acids in the carboxy terminal region.
    Type: Grant
    Filed: January 27, 1992
    Date of Patent: May 3, 1994
    Assignee: Vanderbilt University
    Inventor: R. Stephen Lloyd
  • Patent number: 5266475
    Abstract: A genetically engineered glucose isomerase with improved affinity for D-glucose and the method of preparation of such a glucose isomerase are disclosed. The glucose isomerase is obtained by mutagenizing the gene of a naturally occurring glucose isomerase such that a smaller amino acid replaces a larger amino acid in the catalytic site. In an especially advantageous embodiment of the present invention, the Clostridium glucose isomerase sequence is mutated and the residue replaced with a smaller amino acid is either Trp.sub.139 or Val.sub.186.
    Type: Grant
    Filed: September 19, 1991
    Date of Patent: November 30, 1993
    Assignee: Michigan Biotechnology Institute
    Inventors: Chanyong Lee, Michael Bagdasarian, J. Gregory Zeikus, Menghsiao Meng